GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

MBX Biosciences MBX · USD

Health Care · US listing · 🇺🇸 United States

Compare

54.06

+5.28%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About MBX Biosciences

From its filings with the US Securities and Exchange Commission

SEC filings

MBX Biosciences is based in Carmel, Indiana and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker MBX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $87.0m. At that date it held total assets of $385.1m and shareholders' equity of $369.2m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
13 Sept 2024
Employees
63
Website
mbxbio.com ↗
Head office
11711 N. MERIDIAN STREET, CARMEL, IN, 46032
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. P. Kent HawrylukPresident, Chief Executive Officer, Director, since 2019$2.2m
  • Mr. Richard BartramChief Financial Officer$1.2m
  • Dr. Salomon AzoulayChief Medical Officer$3.1m
  • Mr. Patrick HeronLead Independent Director$213,309
  • Dr. Tiba AynechiIndependent Director$207,058
  • Mr. James CorneliusIndependent Director$366,729
  • Mr. Steven HoerterIndependent Director
  • Mr. Edward MathersIndependent Director$205,750
  • Ms. Ora PescovitzIndependent Director$422,261
  • Dr. Steven RyderIndependent Director$478,955
  • Mr. Jim DenikeSenior Director - Investor Relations and Communications, since 2025

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
35
Environment
37
Social
40
Governance
28
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • MBX Biosciences has a proprietary Precision Endocrine Peptide platform for developing novel therapies.
  • MBX 2109 targets chronic hypoparathyroidism with a long-acting hormone replacement therapy.
  • MBX 1416 addresses post-bariatric hypoglycemia as a potential GLP-1 receptor antagonist.

Weaknesses

  • The company has only 36 full-time employees, which may limit operational capacity.
  • MBX Biosciences is a clinical-stage biopharmaceutical company with limited commercial experience.
  • The IPO on 13 September 2024 indicates recent market entry with unproven revenue streams.

Opportunities

  • The Obesity portfolio offers potential growth in the expanding metabolic disorder treatment market.
  • The US market provides a significant opportunity for endocrine and metabolic disorder therapies.
  • The Precision Endocrine Peptide platform can be leveraged for additional therapeutic applications.

Threats

  • Competition from established pharmaceutical companies in the Health Care sector.
  • Regulatory hurdles may delay the approval of MBX 2109 and MBX 1416.
  • The clinical-stage status poses risks of trial failures for product candidates.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.